Presentations featured overviews of company’s operations, technology and plans for the future

AUSTIN, Texas — Luminex Corporation (NASDAQ:LMNX) , the worldwide leader in multiplexed solutions, presented new strategic initiatives at its Annual Investor Day, which was held today at the NASDAQ MarketSite in New York, NY. The event featured presentations from scientists and company executives and included a review of Luminex’s innovative product pipeline, the announcement of the company’s acquisition of Australian-based BSD Robotics, the unveiling of an exclusive collaboration and licensing agreement with Advanced Liquid Logic, and details regarding Luminex’s biothreat initiative.

(Logo: http://www.newscom.com/cgi-bin/prnh/20100104/LUMINEXLOGO)

The Annual Investor Day kicked off with Patrick J. Balthrop, president and chief executive officer of Luminex, ringing the NASDAQ Stock Market Opening Bell in commemoration of Luminex’s 10th anniversary as a NASDAQ-listed company. Following the opening bell, Luminex executives discussed financial and operational highlights for the company as well as its plans for continued growth, and provided an overview of its pipeline of life science research, agricultural science and diagnostic products.

“The Luminex team was pleased to be at NASDAQ to celebrate our 10-year anniversary of trading on the market,” said Balthrop. “We also were excited to share an update on our operations and outlook on our future plans and opportunities. We believe the strategic initiatives discussed today will allow Luminex to further advance our technology and expand our global market presence across diverse market sectors, from scientific research, to clinical diagnostics, to biodefense and agrobiotechnology.”

The event also featured presentations by industry thought leaders, Dr. Andrea Ferreira-Gonzalez, Professor of Pathology and Director of the Molecular Diagnostics Lab at Virginia Commonwealth University, and Dr. Thomas Joos, Head of Biochemistry, NMI Natural and Medical Sciences Institute at the University of Tuebingen. Dr. Ferreira-Gonzalez and Dr. Joos provided customer perspectives on applications for and benefits of Luminex’s technology in molecular diagnostics and life sciences.

About the BSD Robotics Acquisition

Luminex’s acquisition of BSD Robotics will provide the company access to new technology and products, an innovative development team, and an established presence in important strategic markets.

BSD specializes in automation and robotics in the field of dry sample handling. The privately held company, which was founded in 1991, is headquartered in Brisbane, Queensland, Australia. In addition to its established leadership positions in the worldwide newborn screening and forensics and human identification markets, BSD has developed leading positions in several molecular diagnostics markets.

“BSD is excited to become a part of Luminex. Our companies share a commitment to science, innovation and the highest customer service,” said Allan Morrison, managing director of BSD. “There is great potential to combine our technologies and expertise to create new products and reach scientists in many industry sectors, from genetic testing to animal health.”

About the Advanced Liquid Logic Agreement

As part of Luminex’s exclusive licensing agreement with Advanced Liquid Logic, the companies will collaborate to leverage their respective proprietary technologies and co-develop new analytic systems and assays that will help clinicians and scientists across several strategic markets deliver highly accurate results faster and more efficiently.

Advanced Liquid Logic was founded in 2004 to exploit a patented and proprietary technology for micro-liquid-handling called digital microfluidics. Digital microfluidics is an innovative approach to liquid handling that does not use pipes, pumps or valves. Discrete droplets are manipulated electrically to independently control each droplet. The technology enables highly flexible devices that can be configured in software to execute virtually any assay protocol.

When digital microfluidic technology is combined with Luminex’s xMAP Technology and three dimensional liquid arrays, it provides a very versatile sample preparation and assay delivery platform.

“Our team is very pleased to collaborate with Luminex,” said Richard West, CEO of Advanced Liquid Logic. “By combining Liquid Logic’s digital microfluidic technology with Luminex’s xMAP Technology, we can create smaller, more cost-efficient systems and very streamlined assays that require less hands-on time and provide very fast, accurate results.”

Annual Investor Day presentations will be archived for six months and may be accessed on Luminex’s website: http://www.luminexcorp.com/.

About Luminex Corporation

Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company’s xMAP® multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics markets. The Company’s xMAP Technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP Technology can be obtained at www.luminexcorp.com.